# DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
Canonical URL: https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-2026
Ticker: DMAC
Company: DiaMedica Therapeutics
Source: DiaMedica Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://www.diamedica.com
## Summary

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ...

## Article Body
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026.

Jefferies Global Healthcare Conference

Date: Thursday, June 4, 2026

Time: 3:45 PM ET

Format: Corporate Presentation

If you are interested in arranging a 1×1 meeting with management, please contact your conference representative.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527840935/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

For Investor Inquiries: Mike Moyer

Managing Director, LifeSci Advisors, LLC

Phone: (617) 308-4306

mmoyer@lifesciadvisors.com

Media Contact: Madelin Hawtin

LifeSci Communications

mhawtin@lifescicomms.com

Source: DiaMedica Therapeutics Inc.

Released May 27, 2026
## Recent Company News
- 2026-07-17 20:30 EST — [DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/DMAC/diamedica-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-58a5078e) — Source: DiaMedica Therapeutics
- 2026-06-25 13:46 EST — [DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-first-patients-dosed-in-phase-2-trial-of-dm199-for-the-treatment-of-fetal-growth-restriction) — Source: DiaMedica Therapeutics
- 2026-06-25 13:46 EST — [DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program](https://biopharmsignal.com/news/DMAC/diamedica-receives-fda-feedback-on-dm199-preeclampsia-nonclinical-program) — Source: DiaMedica Therapeutics
- 2026-06-25 13:46 EST — [DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-2026) — Source: DiaMedica Therapeutics
- 2026-06-25 13:46 EST — [DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-75-enrollment-milestone-in-remedy2-phase-2-3-acute-ischemic-stroke-trial) — Source: DiaMedica Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)